Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.59 |
| ▸ | NAAA | Q02083 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | TLR4 | O00206 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14534711 | 1.00 | EPHX1 (0.59) | EPHX1NAAAALDH1A1GAAASAH1 | |
| SCHEMBL18029925 | 0.96 | ALDH1A1 (0.56) | EPHX1NAAAALDH1A1GAAASAH1 | |
| SCHEMBL4639581 | 0.96 | ALDH1A1 (0.56) | EPHX1NAAAALDH1A1GAAASAH1 | |
| SCHEMBL425375 | 0.90 | ALDH1A1 (0.58) | EPHX1NAAAALDH1A1GAATSHR | |
| SCHEMBL13877120 | 0.83 | EPHX1 (0.55) | EPHX1NAAAALDH1A1GAAASAH1 | |
| SCHEMBL19345760 | 0.82 | EPHX1 (0.57) | EPHX1NAAAALDH1A1GAAASAH1 | |
| SCHEMBL1718075 | 0.82 | TLR4 (0.56) | EPHX1NAAAALDH1A1GAATSHR | |
| SCHEMBL22469123 | 0.81 | CTSK (0.49) | NAAAALDH1A1GAATLR4CTSK | |
| SCHEMBL22469417 | 0.81 | CTSK (0.49) | NAAAALDH1A1GAATLR4CTSK | |
| SCHEMBL22469229 | 0.81 | CTSK (0.49) | NAAAALDH1A1GAATLR4CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2018-03-15 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| US-9775845-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-2685981-B1 | PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | Synchronicity Pharma, Inc. | 2016-07-14 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265772-B2 | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS, INC. (US) | 2016-02-23 | — | — | US | disclosed |
| CN-104640856-A | Carbazole-containing sulfonamides as cryptochrome modulators | RESET THERAPEUTICS INC | 2015-05-20 | — | — | CN | disclosed |
| US-8921368-B2 | Pyrrolopyridazine JAK3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-12-30 | — | — | US | disclosed |
| EP-1951673-A2 | HETEROCYCLIC CETP INHIBITORS | Bristol-Myers Squibb Company (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885NAAA 520/4885ALDH1A1 2353/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | EPHX1 1130/4885NAAA 520/4885ALDH1A1 2353/4885 |
| US-20160200732-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | EPHX1 1879/4885NAAA 3418/4885ALDH1A1 1829/4885 |
| US-20180071306-A1 | CARBAZOLE-CONTAINING SULFONAMIDES AS CRYPTOCHROME MODULATORS | CRY1, CRY2, CRYAB | EPHX1 1879/4885NAAA 3418/4885ALDH1A1 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.